Pasithea Therapeutics
KTTA | NASDAQ
$0.50
-$0.01 (-2.67%)
At close: Sep 25, 2026, 4:00 PM ET
-2.67%
(1D)Rating
Key Statistics
Market Data
Market Cap $16.68M
1D Range
0.49 0.51
52W Range
0.28 2.06
Valuation (TTM)
PE -0.20
PB 0.33
EV/EBITDA 1,958.94
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $3.00
Cash Flow
FCF Yield -106.6%
SBC Adj. FCF Yield -2919.8%
SBC Impact -2639.0%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
-100.0%
Dil EPS 3Y | 5Y 69.7% |
43.0%
FCF 3Y | 5Y -9.6% |
-12.2%
Returns
ROA -41.2%
ROE -49.5%
ROIC -48.0%
Financial Health
Net Cash
$45.66B
Current Ratio 26.25
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its ...
Sector Healthcare
Industry Biotechnology
Employees 5
IPO Date Sep 15, 2021
Website www.pasithea.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$3.00
Upside
+500.00%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove KTTA